| Autor: |
Evers LJ; Koraalgroup, MFCG,Heel,The Netherlands., Curfs LM; Governor Kremers Centre, Maastricht University Medical Centre,Maastricht,The Netherlands., Bakker JA; Department Clinical Genetics,Maastricht University Medical Centre,Maastricht,The Netherlands., Boot E; Ipse de Bruggen, Centre for People with intellectual disability,Zwammerdam,The Netherlands., da Silva Alves F; Department of Psychiatry,Academic Medical Centre, University of Amsterdam,Amsterdam,The Netherlands., Abeling N; Department of Genetic Metabolic Disorders,AMC,Amsterdam,The Netherlands., Bierau J; Department Clinical Genetics,Maastricht University Medical Centre,Maastricht,The Netherlands., Drukker M; Department of Psychiatry and Psychology,School for Mental Health and Neuroscience MHeNS, Maastricht University Medical Centre,Maastricht,The Netherlands., van Amelsvoort TA; Department of Psychiatry and Psychology,School for Mental Health and Neuroscience MHeNS, Maastricht University Medical Centre,Maastricht,The Netherlands. |
| Abstrakt: |
Patients with 22q11 deletion syndrome (22q11DS) have a high prevalence of psychiatric disorders and intellectual disability. At present the neurobiology underlying psychopathology in 22q11DS is still not understood. In the present study, we analyzed urinary serotonergic, dopaminergic and noradrenergic markers in 67 adults with 22q11DS. Levels of serotonin and the catecholamine metabolite homovanillic acid were significantly lower in the 22q11DS subjects compared to healthy controls. Within the 22q11DS group, levels of dopamine, homovanillic acid, norepinephrine, vanillyl mandelic acid and serotonin positively correlated with Full Scale Intelligence Quotient scores. Our results suggest that cognitive deficits in 22q11DS are associated with abnormal function of several neurotransmitters. |
